VBIO

Business Context and Reporting Period

This summary covers the Form 10-Q for Tivic Health Systems, Inc. (Ticker: TIVC) for the quarterly period ended September 30, 2025. The company is a late-stage therapeutics firm transitioning from a consumer healthtech business (ClearUP device) to a biopharmaceutical focus centered on the TLR5 agonist Entolimod for Acute Radiation Syndrome (ARS) and neutropenia. In November 2025, the Board approved the wind-down of the ClearUP business, expecting minimal to no revenue from this segment by year-end.

Key Financial Metrics

Note: Q3 2025 Gross Loss includes a $230,000 inventory reserve for obsolete ClearUP inventory and a $117,000 loss on disposal of manufacturing molds.

Material Changes vs. Prior Period

• Revenue Decline (9M): Revenue decreased 50% year-over-year ($302k vs $600k) due to a 45% drop in unit sales and reduced advertising spend as the company pivots away from the consumer business.
• Expense Surge: Operating expenses increased 33% in Q3 and 33% for the 9-month period. R&D expenses doubled in Q3 ($858k vs $422k) driven by the new biopharma program (Entolimod) and manufacturing validation costs.
• Inventory Write-downs: A significant $230,000 charge was recorded in Q3 for excess and obsolete inventory related to the ClearUP wind-down, turning a positive gross margin into a loss.
• Capital Structure: The company completed four tranches of a "Tranched Financing" agreement, raising approximately $4.9 million in gross proceeds via Series B Preferred Stock and warrants. A 1-for-17 reverse stock split was implemented in March 2025.

Outlook, Risks, and Management Commentary

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern within one year. With a cash balance of $3.5 million and a burn rate driven by biopharma development, additional financing is required to fund operations and clinical trials.
• Strategic Pivot: The company is exiting the ClearUP consumer business. Future revenue is contingent on regulatory approval and commercialization of Entolimod. Management expects minimal revenue until these milestones are met.
• Manufacturing Risks: The contract manufacturer for Entolimod (Scorpius BioManufacturing) is experiencing financial distress, causing delays in the clinical development timeline. The company is evaluating alternative manufacturers.
• Regulatory & Government Risks: A prolonged U.S. federal government shutdown (occurring Oct-Nov 2025) has delayed SEC registration effectiveness for future financing tranches and may delay FDA review of submissions.
• Future Funding: The company has an Equity Line of Credit with Mast Hill ($25M capacity) and an active tranched financing agreement with an investor (up to $8.4M total). Two tranches remain to be closed under the preferred stock agreement.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.5M cash balance against the projected burn rate for the biopharma transition and the timeline for closing the remaining two tranches of the $8.4M financing.
• Manufacturing Stability: Confirm the status of the Scorpius BioManufacturing contract and the timeline for securing an alternative manufacturer if Scorpius ceases operations.
• ClearUP Wind-down Costs: Monitor the actual costs incurred during the wind-down of the ClearUP business against the estimated $20k-$50k remaining expenditure.
• Financing Dilution: Assess the dilution impact of the Series B Preferred Stock (convertible with a floor price) and the extensive warrant issuances (over 1M shares outstanding) on future equity value.
• Regulatory Timeline: Track the impact of the federal government shutdown on the effectiveness of registration statements required for future capital raises and FDA review processes.